Delving into the Latest Updates on Recombinant fowlpox gp100 virus vaccine(NCI) with Synapse

Overview

Basic Info

Drug Type

Recombinant vector vaccine, Therapeutic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Melanoma recurrentMelanoma, Cutaneous MalignantMetastatic melanoma

Originator Organization

National Cancer Institute

Active Organization-

Inactive Organization

National Cancer Institute

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic melanoma.
PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2 with that of melanoma vaccine alone in treating patients who have metastatic melanoma that has not responded to previous treatment.

Start Date01 Oct 1999

Sponsor / Collaborator

National Cancer Institute

NCT00019175

/ CompletedPhase 1IIT

PHASE I TRIAL IN PATIENTS WITH METASTATIC MELANOMA OF IMMUNIZATION WITH A RECOMBINANT FOWLPOX VIRUS ENCODING THE GP100 MELANOMA ANTIGEN

RATIONALE: Vaccines made from an antigen combined with a modified virus may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy with interleukin-2 may kill more tumor cells.
PURPOSE: Phase I trial to compare the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have recurrent metastatic melanoma that has not responded to previous therapy.

Start Date01 Aug 1996

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Recombinant fowlpox gp100 virus vaccine(NCI)

Login to view more data

100 Translational Medicine associated with Recombinant fowlpox gp100 virus vaccine(NCI)

Login to view more data

100 Patents (Medical) associated with Recombinant fowlpox gp100 virus vaccine(NCI)

Login to view more data

100 Deals associated with Recombinant fowlpox gp100 virus vaccine(NCI)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma, Cutaneous Malignant	Phase 2	United States	National Cancer Institute	01 Oct 1999
Metastatic melanoma	Phase 2	United States	National Cancer Institute	01 Oct 1999
Melanoma recurrent	Phase 2	United States	National Cancer Institute	01 Aug 1996